ProCE Banner Activity

Advances in Relapsed/Refractory Multiple Myeloma: Practical Guidance for Newly Approved and Emerging Therapies

Slideset Download
Download these slides from a live webinar for the most recent data on the optimal treatment options for patients with relapsed or refractory myeloma, including information on how to incorporate these agents into your current clinical practice.

Released: May 04, 2021

Expiration: May 03, 2022

No longer available for credit.

Share

Faculty

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Kathryn Maples

Kathryn Maples, PharmD, BCOP

Clinical Pharmacy Specialist, Multiple Myeloma
Department of Pharmacy
Emory Healthcare
Winship Cancer Institute
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Bristol Myers Squibb

Karyopharm Therapeutics

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Kathryn Maples, PharmD, BCOP

Clinical Pharmacy Specialist, Multiple Myeloma
Department of Pharmacy
Emory Healthcare
Winship Cancer Institute
Atlanta, Georgia